Page 183 - Haematologica-April 2018

Tocilizumab for the prevention of acute GvHD
11. Cavet J, Dickinson AM, Norden J, Taylor PRA, Jackson GH, Middleton PG. Interferon γ and interleukin 6 gene poly- morphisms associate with graft versus host disease in HLA-matched sibling bone mar- row transplantation. Blood. 2001;98(5): 1594-1600.
12. Socie G, Loiseau P, Tamouza R, et al. Both genetic and clinical factors predict the development of graft versus host disease after allogeneic hematopoietic stem cell transplantation. Transplantation. 2001; 72(4):699-706.
13. Alam N, Xu W, Atenafu EG, et al. Risk model incorporating donor IL-6 and IFNG genotype and gastrointestinal GVHD can discriminate patients at high risk of steroid refractory acute GVHD. Bone Marrow Transplant. 2015;50(5):734-742.
14. Chien JW, Zhang XC, Fan W, et al. Evaluation of published single nucleotide polymorphisms associated with acute GVHD. Blood. 2012;119(22):5311-5319.
15. Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin 6 receptor anti- body. Arthritis Rheum. 2004;50(6):1761- 1769.
16. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-con- trolled, withdrawal phase III trial. Lancet. 2008;371(9617):998-1006.
17. Drobyski WR, Pasquini M, Kovatovic K, et al. Tocilizumab for the treatment of steroid refractory graft versus host disease. Biol Blood Marrow Transplant. 2011; 17(12):1862-1868.
18. Kennedy GA, Varelias A, Vuckovic S, et al. Addition of interleukin 6 inhibition with tocilizumab to standard graft versus host disease prophylaxis after allogeneic stem cell transplantation: a phase 1/2 trial. Lancet Oncol. 2014;15(13):1451-1459.
19. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradiation, busulfan-cyclophos- phamide, or cyclophosphamide condition- ing on inflammatory cytokine release and development of acute and chronic graft ver- sus host disease in H-2 incompatible trans- planted SCID mice. Blood. 1994; 83(8):2360-2367.
20. D'Souza A, Lee S, Zhu X, Pasquini M. Current use and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2017; 23(9):1417-1421.
21. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow
Transplant. 1995;15(6):825–828.
22. Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft versus host disease: I. The 2014 diagnosis and staging working group. Biol Blood Marrow Transplant.
2015;21(3):389-401.
23. Armand P, Kim HT, Logan BR, et al.
al. Response of 443 patients to steroids as primary therapy for acute graft versus host disease: comparison of grading systems. Biol Blood Marrow Transplant. 2002;8(2): 387-394.
34. Castilla-Llorente C, Martin PJ, McDonald GB, et al. Prognostic factors and outcomes of severe gastrointestinal GVHD after allo- geneic hematopoietic cell transplantation. Bone Marrow Transplant. 2014;49(7):966-
Validation and refinement of the disease
risk index for allogeneic stem cell transplan- 971.
tation. Blood. 2014;123(23):3664-3671.
24. Wehr C, Eibel H, Masilamani M, et al. A new CD21low B cell population in the peripheral blood of patients with SLE. Clin
Immunol. 2004;113(2):161-171.
25. Isnardi I, Ng YS, Menard L, et al.
Complement receptor 2/CD21− human naive B cells contain mostly autoreactive unresponsive clones. Blood. 2010;115(24): 5026-5036.
26. Shirota Y, Yarboro C, Fischer R, Pham TH, Lipsky P, Illei GG. Impact of anti-inter- leukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis. 2013;72(1):118-128.
27. Greinix HT, Pohlreich D, Kouba M, et al. Elevated numbers of immature/transitional CD21− B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host dis- ease. Biol Blood Marrow Transplant. 2008;14(2):208-219.
28. Kuzmina Z, Krenn K, Petkov V, et al. CD19(+)CD21(low) B cells and patients at risk for NIH-defined chronic graft-versus- host disease with bronchiolitis obliterans syndrome. Blood. 2013;121(10):1886-1895.
29. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft versus host disease: the role of gastrointestinal damage and inflamma- tory cytokines. Blood. 1997;90(8):3204- 3213.
30. Flowers ME, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft versus host disease and for chronic graft versus host disease according to National Institutes of Health consensus criteria. Blood. 2011;117(11):3214-3219.
31. McDonald GB, Tabellini L, Storer BE, Lawler RL, Martin PJ, Hansen JA. Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measure- ments before GVHD onset and treatment. Blood. 2015;126(1):113-120.
32. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic cell transplantation. New Engl J Med. 2010;363(22):2091-2101.
33. MacMillan ML, Weisdorf DJ, Wagner JE, et
35. Macmillan ML, Robin M, Harris AC, et al. A refined risk score for acute graft versus host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant. 2015;21(4):761-767.
36. Ferrara JL, Harris AC, Greenson JK, et al. Regenerating islet-derived 3-alpha is a bio- marker of gastrointestinal graft versus host disease. Blood. 2011;118(25):6702-6708.
37. Pidala J, Anasetti C. Glucocorticoid-refrac- tory acute graft versus host disease. Biol Blood Marrow Transplant. 2010; 16(11):1504-1518.
38. Jamani K, RussellJA, Daly A, et al. Prognosis of grade 3-4 acute GVHD contin- ues to be dismal. Bone Marrow Transplant. 2013;48(10):1359-1361.
39. Mielcarek M, Storer BE, Boeckh M, et al. Initial therapy of acute graft versus host disease with low dose prednisone does not compromise patient outcomes. Blood. 2009;113(13):2888-2894.
40. Castilla C, Perez-Simon JA, Sanchez-Guijo FM, et al. Oral beclomethasone dipropi- onate for the treatment of gastrointestinal acute graft versus host disease (GVHD). Biol Blood Marrow Transplant. 2006;12(9):936-941.
41. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leuk Biol. 2006;80(2):227-236.
42. Mullberg J, Schooltink H, Stoyan T, et al. The soluble interleukin 6 receptor is gener- ated by shedding. Eur J Immunol. 1993;23(2):473-480.
43. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM. The soluble interleukin-6 receptor: mechanisms of production and implications in disease. FASEB J. 2001;15(1):43-58.
44. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin 6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL- 6-receptor antibody, tocilizumab, in patients with rheumatoid arthritis. Blood. 2008;112(10):3959-3964.
haematologica | 2018; 103(4)
727